lead-radioisotopes and Triple-Negative-Breast-Neoplasms

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor prognosis. There is a clinical need for effective, targeted therapy strategies that destroy both differentiated TNBC cells and TNBC cancer initiating cells (CICs), as the latter are implicated in the metastasis and recurrence of TNBC. Chondroitin sulfate proteoglycan 4 (CSPG4) is overexpressed on differentiated tumor cells and CICs obtained from TNBC patient specimens, suggesting that CSPG4 may be a clinically relevant target for the imaging and therapy of TNBC. The purpose of this study was to determine whether α-particle radioimmunotherapy (RIT) targeting TNBC cells using the CSPG4-specific monoclonal antibody (mAb) 225.28 as a carrier was effective at eliminating TNBC tumors in preclinical models. To this end, mAb 225.28 labeled with

Topics: Animals; Antibodies; Antigens; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clone Cells; Disease Models, Animal; Female; Humans; Lead Radioisotopes; Mice, Nude; Neoplastic Stem Cells; Proteoglycans; Tissue Distribution; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays